C André

Hôpital Henri Mondor (Hôpitaux Universitaires Henri Mondor), Créteil, Île-de-France, France

Are you C André?

Claim your profile

Publications (77)

  • [Show abstract] [Hide abstract] ABSTRACT: There is no evidence that therapeutic drug monitoring is helpful in patients with inflammatory bowel disease patients in clinical remission with infliximab therapy. Eighty consecutive inflammatory bowel disease patients in clinical remission on infliximab maintenance therapy were included and followed-up for at least one year. Infliximab trough level and antibody to infliximab concentration were measured prior to enrollment. At the time of enrollment, physicians in charge were free to alleviate infliximab therapy. Discrepancies between blind and therapeutic drug monitoring-based adjustments were assessed at the end of the follow-up period. Relapse-free survival was analyzed using univariate and multivariate analyses. The mean infliximab trough level was 3.1μg/mL. Antibody to infliximab was found in 15 (19%) patients. At the end of the follow-up period, 18 (22.5%) patients experienced a relapse. The 3, 6, 9 and 12-month relapse-free rates were 98%, 87%, 86% and 80%, respectively. In our multivariate analysis, relapse-free survival was negatively associated with discrepancies between therapeutic drug monitoring-based and blind adjustments of infliximab therapy, absence of concomitant immunomodulator, the absence of mucosal healing, prior use of infliximab, infliximab therapy duration>2years and C-reactive protein levels>5mg/L at the time of enrollment. In patients with inflammatory bowel disease in clinical remission on infliximab therapy, de-escalation of infliximab therapy should be considered based on therapeutic drug monitoring rather than according to symptoms and CRP. Copyright © 2015 Elsevier Masson SAS. All rights reserved.
    Article · Jun 2015 · Gastroentérologie Clinique et Biologique
  • Nathalia Bellon · Chantal André · Emilie Sbidian · [...] · Saskia Ingen-Housz-Oro
    [Show abstract] [Hide abstract] ABSTRACT: Background: The value of anti-desmoglein 1 and 3 (Dsg1, Dsg3) enzyme-linked immunosorbent assay (ELISA) is controversial in the follow-up of pemphigus. Objective: To evaluate anti-desmoglein ELISA (Dsg ELISA) in the follow-up of pemphigus and compare ELISA with direct and indirect immunofluorescence in complete remission (CR). Methods: We performed a retrospective monocenter study of patients with pemphigus and consecutive sera samples collected at baseline (M0), 12 months (M12) and 24 or 36 months after M0 (M24/36). Tests were compared in CR and in active disease. Direct immunofluorescence and circulating autoantibodies were compared for patients with stable CR. Results: We included 36 patients. At M12, ELISA values did not differ between CR and active disease. At M24/36, Dsg3 but not Dsg1 ELISA values were lower in CR (p = 0.07). For 5/8 patients with stable CR, direct immunofluorescence and ELISA findings remained positive. Conclusion: In routine practice, Dsg ELISA seems to be of little interest for immunological follow-up of pemphigus. © 2014 S. Karger AG, Basel.
    Article · Sep 2014 · Dermatology
  • [Show abstract] [Hide abstract] ABSTRACT: D-penicillamine may induce several cutaneous adverse events, the most frequent being elastosis perforans serpiginosa (EPS) and pemphigus vulgaris.1 Cases of epidermolysis bullosa acquisita (EBA)-like reactions have been rarely described and not immunologically confirmed.2 Here, we report 2 family-related cases of EBA-like reaction and hypothesize that D-penicillamine could induce anti-collagen VII autoimmunity. A lady and her brother in their thirties, whose parents were first cousins, were referred for hemorrhagic blisters and skin fragility on their elbows and knees.This article is protected by copyright. All rights reserved.
    Article · Jun 2014 · British Journal of Dermatology
  • Article · Dec 2013 · Annales de Dermatologie et de Vénéréologie
  • N. Bellon · C. André · E. Sbidian · [...] · S. Oro
    Article · Dec 2013 · Annales de Dermatologie et de Vénéréologie
  • Article · Aug 2013 · Annales de Dermatologie et de Vénéréologie
  • [Show abstract] [Hide abstract] ABSTRACT: Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering skin disorder characterized by linear deposits of immunoglobulin A (IgA) along the dermoepidermal junction visualized by direct immunofluorescence (DIF). It is usually spontaneous and drug-induced. To compare clinical and histological LABD forms. This retrospective monocenter cohort study concerned 28 patients diagnosed with LABD from 1 January 1995 to 31 December 2010. Imputability determined according to the French imputability method (modified Bégaud score) and Naranjo scores, enable constitution of drug-induced or spontaneous LABD groups, whose clinical and histological features were compared with blinded analysis of images and histological patterns. Sixteen patients had spontaneous LABD and 12 had drug-induced LABD. Nikolsky's sign and large erosions were significantly more frequent in drug-induced than spontaneous LABD (P=0·003 and P=0·03 respectively), with no between-group differences for erythematous plaques, target or target-like lesions, string of pearls, location, mucosal involvement or histological features. Drug-induced LABD was more severe than the spontaneous form, with lesions mimicking toxic epidermal necrolysis. Because LABD may be polymorphic and sometimes life-threatening, DIF assay is recommended for all patients with Nikolsky's sign and large erosions. This article is protected by copyright. All rights reserved.
    Article · Jul 2013 · British Journal of Dermatology
  • Source
    Nicolas Noel · Chantal André · Djaouida Bengoufa · [...] · Sophie Hüe
    [Show abstract] [Hide abstract] ABSTRACT: Anti-neutrophil cytoplasmic (ANCA) directed against proteinase 3 (PR3-ANCA) are a serological hallmark of small vessel vasculitis, particularly granulomatous with polyangiitis (GPA). To increase their sensitivity, some ELISA employ the human native PR3 combined with a recombinant protein. Their specificity in daily practice is still to be defined. Our objective was to compare the performance for GPA diagnosis of three PR3-ANCA assays in daily practice. Seventy-eight consecutive patients' sera with suggestive IIF. All sera were tested with a routine Enzyme Linked Immuno Assay (ELISA) employing a mixture of human native and human recombinant (hn+hr) PR3 (EUROIMMUN(TM)) compared to two assays using immobilized purified human PR3 (QUANTA Lite(TM) ELISA and QUANTA Flash(TM) Chimiluminescent assay (CIA), INOVA Diagnostics). Clinical data including BVAS score were collected retrospectively. Nineteen out of the 78 patients had GPA. The hn+hr PR3 ELISA had a good sensitivity (100%) but a lower specificity for the diagnosis of GPA (61.0%) than the assays using the sole native protein (hn ELISA: 81.4%, hn CIA: 69.5%). False positive results mainly consisted of patients with inflammatory bowel disease, who had a specific PR3-ANCA positivity assembly when coupling the assays. The antibody titers by human native PR3 assays, but not hn+hr assay, positively correlated with BVAS score. These results highlight the need of a close collaboration between physicians and immunologists. Combining assays including last generation CIA employing human native antigens should improve the performance of GPA's diagnosis.
    Full-text available · Article · Jun 2013 · Autoimmunity reviews
  • Article · Jun 2012 · Journal of the American Geriatrics Society
  • Source
    N. Noel · C. Andre · D. Bengoufa · [...] · S. Hue
    Full-text available · Article · Jun 2012 · La Revue de Médecine Interne
  • [Show abstract] [Hide abstract] ABSTRACT: The value of 230-kDa bullous pemphigoid antibody (BP230) enzyme-linked immunosorbent assay (ELISA) for the diagnosis of bullous pemphigoid (BP) was investigated, but in the immunological follow-up of the disease remains unknown. Evaluation of BP230 ELISA for diagnosis, follow-up and prediction of relapse in BP. Monocenter retrospective and prospective study. Patients with typical BP. Detection of autoantibodies by indirect immunofluorescence (IIF), BP180 and BP230 ELISA tests at diagnosis, during the treatment (disease control or failure) and at treatment stop (relapse or not 3 months after). 74 patients were included. At diagnosis, BP230 ELISA sensitivity was lower than IIF and BP180 ELISA. Combining both ELISA added a weak gain of sensitivity. Both tests paralleled the clinical evolution, especially in case of disease control. At the end of the treatment, BP230 ELISA was not different in patients with or without relapse. In routine practice, BP230 ELISA does not seem to be a useful additional test in typical BP.
    Article · Apr 2012 · Dermatology
  • Article · Dec 2011 · Annales de Dermatologie et de Vénéréologie
  • Article · Dec 2011 · Annales de Dermatologie et de Vénéréologie
  • [Show abstract] [Hide abstract] ABSTRACT: The usefulness of immumoglobulin (Ig) A antibodies to gliadin (AGA-IgA) in addition to IgA anti-endomysium and tissue transglutaminase antibodies was evaluated in 4122 children younger than 2 years with a suspicion of coeliac disease (CD). Eight percent (312/4122) displayed IgA anti-endomysium and/or IgA anti-tissue transglutaminase, whereas 2.1% (85/4122) displayed only AGA-IgA. Clinical data were obtained for 62 of 85 children with isolated AGA-IgA, and 33 children underwent a duodenal biopsy. Histologically proven CD was established for 5 patients, whereas 57 children were diagnosed to experience other diseases. The systematic detection of AGA-IgA using native gliadin conferred no additional diagnostic benefit for the diagnosis of CD in children younger than 2 years of age, except for rare cases.
    Article · Aug 2011 · Journal of pediatric gastroenterology and nutrition
  • Source
    P Ghillani · C André · C Toly · [...] · C Johanet
    [Show abstract] [Hide abstract] ABSTRACT: Ro52 antigen has recently been identified as TRIM21 protein, but the clinical significance of anti-Ro52/TRIM21 antibodies remains controversial. The aim of this multicentric study was to investigate the significance of anti-Ro52 antibodies without anti-SSA/Ro60 antibodies in various connective diseases. Sera were selected by each laboratory using its own method (ELISA, immunodot or Luminex technology), and then performed with ANA Screen BioPlex™ reagent (BIO-RAD). Among the 247 screened sera, 155/247 (63%) were confirmed as anti-Ro52 positive and anti-SSA/Ro60 negative. These sera were analyzed for the detection of other antibodies in relation with clinical settings. Isolated anti-Ro52 antibodies were detected in 89/155 (57%) sera. For the remaining sera (66/155), the main antibodies associations were Sm/SmRNP or Chromatin (n=38; 57%), Jo1 (n=17; 26%) and CenpB (n=9; 14%). Clinical data from the 155 patients showed high prevalence in autoimmune diseases (73%) including myositis or dermatomyositis (n=30), lupus (n=23); Sjögren and/or sicca syndrome (n=27); CREST or Systemic sclerosis (n=11) and autoimmune hepatitis (n=11). We found that pulmonary manifestations were often associated with the presence of anti-Ro52 antibodies (n=34, 22%), in addition with anti-tRNA synthetases, anti-SRP or anti-Ku antibodies (18/34) or isolated in half of cases (16/34). Separate detection of anti-Ro52 antibodies might be useful in related antisynthetase syndrome diagnosis. The presence of anti-Ro52 antibodies should probably precede development of autoimmune disease and must induce sequential follow-up of positive patients, particularly in interstitial lung disease progression.
    Full-text available · Article · Mar 2011 · Autoimmunity reviews
  • [Show abstract] [Hide abstract] ABSTRACT: Erythema elevatum diutinum (EED) is a very rare form of chronic dermatosis clinically characterised by reddish-violet papular nodules extending to the surfaces of the limbs and extremities. Histologically, there are classically two phases of progression initially involving associated neutrophilic dermatosis and leucocytoclastic vasculitis, which is later followed by fibrosis of characteristic appearance. We report the association of EED and pyoderma gangrenosum in a patient infected with HIV. A 53-year-old male seen since 1989 for HIV infection had been presenting firm bilateral and symmetrical nodules on the feet for 6 months. Histological analysis of one of these nodules resulted in diagnosis of chronic erythema elevatum diutinum and treatment with dapsone was initiated. Three months later, despite regression of the EED lesions under dapsone, two large pustules appeared on the outer aspect of the right leg; they were confluent and progressed towards a superficial ulcer with rounded edges with a clinical appearance evocative of pyoderma gangrenosum (PG). Histopathological analysis demonstrated a massive dermal infiltrate beneath the ulcer comprising neutrophils with evidence of leucocytoclasia, all of which militated in favour of the diagnosis of pyoderma gangrenosum. We report for the first time the association of two forms of neutrophilic dermatosis, EED and PG, in an HIV-positive patient. This case report and certain data in the literature suggest that the various forms of neutrophilic dermatosis tend to result in a range of lesions rather than in clearly distinct entities.
    Article · May 2010 · Annales de Dermatologie et de Vénéréologie
  • S. Mignot · C. Prost · C. Andre · [...] · F. Caux
    Conference Paper · Oct 2009
  • Article · Jul 2008 · Revue Francophone des Laboratoires
  • Article · Jul 2008 · Revue Francophone des Laboratoires
  • [Show abstract] [Hide abstract] ABSTRACT: Our objective was to evaluate the prevalence of autoantibodies to cyclic citrullinated peptides (anti-CCP aAbs) in a cohort of patients with a variety of inflammatory or non-inflammatory rheumatic diseases other than rheumatoid arthritis (RA). Six hundred and nine serum samples were tested for anti-CCP aAbs and for rheumatoid factor (RF) using enzyme-linked immunosorbent assays and immunonephelometry. The prevalence of anti-CCP aAbs and RF reached 10% and 25%, respectively, using the positive cutoff value suggested by the manufacturers. Using a higher cutoff value (50 U/ml) for both aAbs, the prevalence was lower with 6% and 16%, respectively. The specificity of both markers for RA thus reached 94% and 84%, respectively. Anti-CCP aAbs were found to be elevated in inflammatory and also in non-inflammatory rheumatic diseases in the same proportion. Clinical data obtained for 36 positive patients showed that 17% developed RA within 5 years. In conclusion, anti-CCP aAbs are clearly more specific than RF for RA. Follow-up of anti-CCP aAbs-positive patients with inflammatory or non-inflammatory rheumatic diseases other than RA could be important considering the predictive value of these aAbs for the development of RA.
    Article · Mar 2008 · Clinical Reviews in Allergy & Immunology

Publication Stats

2k Citations


  • 1991-2013
    • Hôpital Henri Mondor (Hôpitaux Universitaires Henri Mondor)
      • Service de Dermatologie
      Créteil, Île-de-France, France
  • 1988
    • Unité Inserm U1077
      Caen, Lower Normandy, France